Sirnaomics Ltd. — Director's Dealing 2024

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [140 x 41] intentionally omitted <==

Advancing RNAi Therapeutics

Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 2257)

INSIDE INFORMATION

This announcement is made by Sirnaomics Ltd. (the “ Company ”, together with its subsidiaries, the “ Group ”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “ SFO ”).

The board (the “ Board ”) of directors (the “ Director(s) ”) of the Company hereby announces that, on March 17, 2024, the Board was informed by Dr. Xiaochang Dai (“ Dr. Dai ”), an executive Director, that 99,500 shares of the Company (the “ Shares ”) beneficially owned by him and placed in securities accounts of a financial institution with margin facilities, representing approximately 0.11% of the total number of issued Shares as at the date of this announcement, were sold on the market as a result of forced sale (the “ Disposal ”) on March 15, 2024 due to failure in meeting the issued margin calls. The Board was further informed by Dr. Dai that 6,640,500 Shares beneficially owned by him are placed in the securities accounts of the financial institution as collateral with margin facilities for Dr. Dai’s personal financing arrangements, representing approximately 7.58% of the total number of issued Shares as at the date of this announcement. Dr. Dai was also informed by the financial institution on March 15, 2024 that, in the absence of a satisfactory repayment plan, the financial institution will proceed to forcibly sell the 6,640,500 Shares.

To the best knowledge of the Board after having made all reasonable enquiries, immediately following the Disposal and as at the date of this announcement, Dr. Dai was deemed to be interested in an aggregate of 7,828,382 Shares and underlying Shares, within the meaning of Part XV of the SFO.

– 1 –

The Board would also supplement that there is no material adverse change to the Group’s business operation and its research and development. The management team remains highly confident in the long-term prospects of the Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Sirnaomics Ltd. Yang (Patrick) Lu Chairman and Executive Director

Hong Kong, March 17, 2024

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Xiaochang Dai and Dr. David Mark Evans as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.

– 2 –